Author | Eric P. Winer, MD

Articles

POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer

November 16, 2015

We acknowledge that the “more is better” approach may not always hold true. For example, preclinical data provided a rationale for combining pertuzumab with T-DM1, but recent reports suggest that this strategy may not prove more effective than single-agent T-DM1 therapy in the clinic.

The Natural History of Hormone Receptor–Positive Breast Cancer

August 10, 2012

In this article, we describe the long natural history of HR+ breast cancer and review current research and clinical strategies to address this clinical challenge.

Optimizing Endocrine Therapy for Breast Cancer: 'Miles to Go'

January 01, 2007

The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have challenged this standard in postmenopausal women, and ongoing trials are examining the optimal use of endocrine therapy in younger women. Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review.

Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents

May 01, 2003

Hormonal therapies have longplayed an important role inthe treatment of metastaticand early-stage breast cancer. Afterdemonstrating equivalent efficacy andless toxicity than high-dose estrogen,tamoxifen-a selective estrogen-receptormodulator (SERM)-has beenwidely used for the treatment of metastaticbreast cancer.[1] Multiple randomizedadjuvant trials subsequently demonstrated that patients treated withtamoxifen experienced fewer breastcancer recurrences, leading to its widespreaduse in the adjuvant setting.[2]